Hypophosphatemic Rickets with Hypercalciuria (HHRH)

Hypophosphatemic rickets with hypercalciuria (HHRH) is a rare, inherited bone and kidney disorder. The kidneys spill too much phosphate into urine (phosphate wasting). Because phosphate is low in blood, growing bones cannot mineralize well, so children develop rickets (soft, weak bones) and adults can get osteomalacia (bone pain, fractures). Unlike many other forms of hypophosphatemic rickets, HHRH typically has high urinary calcium (hypercalciuria) and often high levels of active vitamin D (1,25-dihydroxyvitamin D), which raises the risk of kidney stones or nephrocalcinosis. Most cases come from loss-of-function variants in the SLC34A3 gene (also called NaPi-IIc), inherited in an autosomal recessive way. ScienceDirect+4PubMed+4ScienceDirect+4 The SLC34A3/NaPi-IIc transporter in the kidney’s proximal tubule normally brings phosphate back into the body. When it does not work, phosphate is lost in urine → blood phosphate falls → bones do not mineralize → rickets/osteomalacia. The body responds by making more active vitamin D (1,25-OH₂D) to absorb more calcium and phosphate from food. That extra calcium is filtered into urine, causing hypercalciuria and sometimes stones. HHRH usually has low or normal FGF23 (unlike XLH), which is another way to distinguish it. PubMed+2PMC+2

Hypophosphatemic rickets with hypercalciuria—often shortened to HHRH—is a rare genetic disorder where the kidneys waste too much phosphate (a mineral bones need). Because phosphate keeps slipping out in the urine, blood phosphate stays low. The body tries to “fix” this by making extra active vitamin D [1,25-(OH)₂D]. That raises calcium absorption from the gut, so calcium in the urine becomes high (hypercalciuria). Children can develop rickets (soft, poorly mineralized bones); teens and adults may have bone pain, short height, and kidney stones or calcium deposits in the kidneys (nephrocalcinosis). Unlike most other hypophosphatemic rickets, HHRH is FGF23-independent (FGF23 is normal or low) and is caused most often by biallelic variants in SLC34A3 (NaPi-IIc), a phosphate transporter in the kidney’s proximal tubule. OUP Academic+2ScienceDirect+2

Key physiology in one line: kidney phosphate wasting → low serum phosphate → low FGF23 & high 1,25-(OH)₂D → increased gut calcium absorption → hypercalciuria ± kidney stones. PMC+1

---

Other names

• HHRH

• Hereditary hypophosphatemic rickets with hypercalciuria (OMIM 241530)

• NaPi-IIc (SLC34A3)–related hypophosphatemic rickets

• FGF23-independent hereditary hypophosphatemic rickets

• Non-FGF23 hypophosphatemic rickets with hypercalciuria
  These labels all point to the same core picture: renal phosphate wasting with high 1,25-(OH)₂D and hypercalciuria due to SLC34A3 dysfunction. ScienceDirect+1

---

Types

1) Classic biallelic SLC34A3 HHRH. Children with two harmful SLC34A3 variants develop hypophosphatemic rickets, high 1,25-(OH)₂D, and hypercalciuria, sometimes with nephrolithiasis or nephrocalcinosis. OUP Academic

2) Partial/heterozygous SLC34A3. Some people with a single variant can have milder features such as kidney stones and hypercalciuria without obvious rickets; families show a spectrum. PubMed

3) SLC34A1 (NaPi-IIa)–related phosphate wasting (HHRH-like). Variants in SLC34A1 can also cause renal phosphate wasting with rickets and hypercalciuria, sometimes labeled as a phenocopy of HHRH. New England Journal of Medicine

4) Age-at-presentation variants. Some patients present in early childhood with bowing legs; others are found later with bone pain or kidney stones discovered on imaging. Merck Manuals

---

Causes

HHRH has one main cause—pathogenic variants in SLC34A3. The list below explains that root cause in detail (different mutation patterns), plus well-documented look-alikes and modifiers that can produce a similar picture of “hypophosphatemic rickets with hypercalciuria” or can worsen it. I clearly note which are primary causes and which are phenocopies/modifiers.

1. Biallelic SLC34A3 loss-of-function (primary). Most classic HHRH results from two damaging variants in SLC34A3; the kidney cannot reclaim phosphate → low serum phosphate, high 1,25-(OH)₂D, hypercalciuria. ScienceDirect+1

2. Compound heterozygous SLC34A3 variants (primary). Two different harmful changes—one on each allele—produce the same physiology and clinical picture. PMC

3. Homozygous SLC34A3 missense variants (primary). A single amino-acid change on both copies can inactivate NaPi-IIc enough to cause full HHRH. PMC

4. Homozygous nonsense/frameshift SLC34A3 variants (primary). Truncating mutations can abolish transporter function, leading to severe renal phosphate wasting. PMC

5. SLC34A3 splice-site variants (primary). Splicing defects disrupt protein making, again causing phosphate loss. PMC

6. Large deletions/insertions in SLC34A3 (primary). Structural variants that remove critical exons lead to HHRH. PMC

7. Promoter/regulatory SLC34A3 variants (primary, rarer). Reduced gene expression can lower transporter amount and cause HHRH. (Described in variant series.) PMC

8. SLC34A3 variants with kidney-predominant features (primary). Some families present mainly with stones/hypercalciuria and only subtle bone disease. ScienceDirect

9. SLC34A1 (NaPi-IIa) pathogenic variants (phenocopy). NaPi-IIa loss can also cause renal phosphate wasting with rickets and hypercalciuria, mimicking HHRH. New England Journal of Medicine

10. Dent disease (CLCN5/OCRL) (phenocopy). X-linked proximal tubulopathy that can produce hypophosphatemic rickets and hypercalciuria—but with low-molecular-weight proteinuria and other tubular losses (clues against HHRH). PMC+1

11. Fanconi syndrome from medications (phenocopy). Proximal tubular injury (e.g., from tenofovir disoproxil fumarate) causes phosphate wasting and osteomalacia; some cases show hypercalciuria. PMC+1

12. Inherited Fanconi syndromes (phenocopy). Genetic proximal tubular disorders (e.g., X-linked forms) can cause rickets via phosphate loss; hypercalciuria may occur. PMC

13. High dietary sodium (modifier). High sodium intake increases urinary calcium loss and can worsen hypercalciuria in people with renal phosphate wasting. NCBI

14. High calcium or vitamin D supplementation (modifier). Extra calcium or active vitamin D raises urinary calcium and may exacerbate stones in HHRH (calcitriol is generally avoided in HHRH). PubMed+1

15. Dehydration/low fluid intake (modifier). Concentrated urine raises stone risk in patients with hypercalciuria. NCBI

16. Reduced phosphate intake (modifier). Low phosphate diet further lowers serum phosphate and can aggravate rickets. (Background hypophosphatemia physiology.) NCBI

17. Pregnancy/lactation stress on minerals (modifier). Mineral demands change; in predisposed individuals, urinary calcium can rise and stones may appear. (General hypercalciuria/stone risk physiology.) NCBI

18. Renal calcifications themselves (vicious cycle). Nephrocalcinosis can reduce tubular function over time and worsen losses. (Stone/hypercalciuria literature.) NCBI

19. Other proximal tubule toxins (phenocopy). Ifosfamide and some antivirals/antibiotics can cause acquired Fanconi-type phosphate wasting with rickets. PMC

20. Mis-treatment with calcitriol in unrecognized HHRH (iatrogenic aggravator). Active vitamin D is standard in FGF23-driven rickets but worsens hypercalciuria in HHRH; correct diagnosis matters. PMC+1

---

Symptoms

1. Bowing of legs or knock-knees. Soft, undermineralized bone in growing children bends under body weight, producing visible deformities. Merck Manuals

2. Wrist and knee swelling. Wide growth plates and metaphyseal changes feel “spongy” or enlarged on exam in active rickets. Merck Manuals

3. Delayed growth and short height. Chronic phosphate shortage slows bone growth, leading to short stature if untreated. Merck Manuals

4. Bone pain and tenderness. Poorly mineralized bone and micro-fractures cause aching pain, often in legs or ribs. Merck Manuals

5. Muscle weakness or fatigue. Low phosphate impairs energy (ATP) use in muscle; children may tire easily or have trouble climbing stairs. NCBI

6. Delayed walking or motor milestones. Weak bones and muscles slow gross motor development. Merck Manuals

7. Waddling gait. Hip and leg deformities alter walking pattern. Merck Manuals

8. Tooth problems. Hypomineralized dentin can mean fragile teeth, caries, or abscesses in some forms of hypophosphatemic rickets. (General rickets literature.) Nature

9. Kidney stones. Extra urinary calcium can crystallize and form painful stones, sometimes the first adult sign. OUP Academic

10. Nephrocalcinosis. Calcium deposits inside kidney tissue show up on ultrasound and may reduce kidney function over years. OUP Academic

11. Frequent urination or urgency. Stones or tubular dysfunction can irritate the urinary tract. (Stone/hypercalciuria data.) NCBI

12. Fractures or pseudofractures. Poor bone mineralization raises the risk of breaks with minor trauma. Merck Manuals

13. Back pain. Vertebral involvement or stones can cause persistent back discomfort. (Bone/stone literature.) NCBI

14. Normal or low-normal calcium in blood. Calcium in the urine is high, but blood calcium is often normal because of high 1,25-(OH)₂D. PMC

15. No obvious FGF23-type signs. Unlike FGF23-driven rickets, HHRH tends to show low/normal FGF23 and high 1,25-(OH)₂D. PMC

---

Diagnostic tests

A) Physical examination

1. Growth and body proportions. Measure height/weight and compare with age charts; chronic hypophosphatemia stunts growth. Merck Manuals

2. Limb alignment check. Look for genu varum/valgum (bowing/knock-knees) and anterior tibial curvature, classic for rickets. Merck Manuals

3. Wrist, knee, and costochondral palpation. Widened wrists/knees and a “rachitic rosary” at the rib ends are common in active rickets. Merck Manuals

4. Gait assessment. Waddling gait or pain with walking often reflects lower-limb deformity and bone tenderness. Merck Manuals

B) Simple manual/bedside maneuvers

5. Shin and rib tenderness testing. Gentle pressure can reproduce pain where undermineralized bone is stressed. Merck Manuals

6. Functional strength tests. Sit-to-stand or stair-climb performance helps gauge muscle weakness from phosphate deficiency. NCBI

7. Dental inspection. Look for enamel or dentin defects and early caries that suggest chronic mineralization problems. Nature

C) Laboratory and pathological tests

8. Serum phosphate (low). Persistent hypophosphatemia is the biochemical hallmark. Use age-specific ranges in children. NCBI

9. Serum calcium (often normal). Despite high urine calcium, blood calcium is usually normal in HHRH. PMC

10. Alkaline phosphatase (elevated). Reflects high bone turnover in active rickets/osteomalacia. Wiley Online Library

11. 1,25-(OH)₂D (elevated). High active vitamin D distinguishes HHRH from FGF23-driven rickets (where it’s low/normal). ScienceDirect

12. FGF23 (low/normal). Helps point to a non-FGF23 mechanism like HHRH or Fanconi. PMC+1

13. Urine calcium (elevated). Spot calcium/creatinine ratio or 24-hour urine confirms hypercalciuria; stone risk correlates with this. NCBI

14. Renal phosphate handling (TmP/GFR). Calculating tubular maximum phosphate reabsorption per GFR confirms renal phosphate wasting. OUP Academic

15. Genetic testing (SLC34A3 ± SLC34A1). Identifies pathogenic variants and clarifies family risk; guides correct therapy (avoid calcitriol). ScienceDirect+1

D) Electrodiagnostic tests

16. Electromyography (optional). In marked hypophosphatemia with muscle symptoms, EMG can show myopathic changes; used when weakness is prominent. NCBI

17. Electrocardiogram (optional). Severe electrolyte disturbances can rarely affect rhythm; ECG is prudent in symptomatic or severely depleted patients. NCBI

E) Imaging

18. Skeletal X-rays. Show widened growth plates, metaphyseal cupping/fraying, and Looser zones/pseudofractures in osteomalacia. Merck Manuals

19. Renal ultrasound. Screens for nephrocalcinosis and stones, common with long-standing hypercalciuria. OUP Academic

20. Bone density (DXA) or bone age. Assesses overall mineralization and growth delay; useful for monitoring recovery on treatment. Merck Manuals

Non-pharmacological treatments (therapies & daily measures)

1. Regular, divided meals with phosphate-containing foods – Purpose: support bone mineralization alongside prescribed phosphate. Mechanism: each meal delivers small phosphate amounts that the gut can absorb; small frequent dosing matches how medical phosphate is also given. ec.bioscientifica.com

2. High-fluid intake (≥2 L/day for older children/adults, as allowed by your clinician) – Purpose: dilute urine to lower stone risk. Mechanism: more water lowers calcium/phosphate concentration in urine so crystals are less likely to form. ScienceDirect

3. Salt restriction – Purpose: reduce urinary calcium loss and stone risk. Mechanism: less sodium intake reduces calcium excretion in the distal nephron, which can lower hypercalciuria. FDA Access Data

4. Balanced calcium (not high-dose) diet – Purpose: maintain normal calcium without driving extra urine calcium. Mechanism: steady dietary calcium supports bone but avoids large surges that can increase calciuria in HHRH. PMC

5. Avoid unnecessary active vitamin D (calcitriol/alfacalcidol) unless your specialist explicitly prescribes it – Purpose: prevent worsening hypercalciuria and stones. Mechanism: active vitamin D raises intestinal calcium absorption → more urinary calcium; in HHRH it’s often already high. PMC+1

6. Fracture-safe physical activity (weight-bearing as tolerated) – Purpose: build bone and muscle safely. Mechanism: gentle loading stimulates bone formation; programs are adapted to rickets/osteomalacia to reduce fracture risk. ec.bioscientifica.com

7. Physiotherapy for alignment, gait, and muscle strength – Purpose: ease pain, improve function during bone healing. Mechanism: targeted exercises improve joint mechanics while bones mineralize under treatment. ec.bioscientifica.com

8. Orthotics / guided bracing in growing children – Purpose: support limb alignment while rickets heals. Mechanism: controlled mechanical support reduces deforming forces on soft bone. ec.bioscientifica.com

9. Stone prevention education (timed voiding, avoiding dehydration during fevers/exercise) – Purpose: practical habits that cut stone risk. Mechanism: frequent urination and hydration lower dwell time and supersaturation of crystals. ScienceDirect

10. Nutrition counseling – Purpose: match daily phosphate, calcium, and protein targets with medical therapy. Mechanism: individualized plans optimize bone mineralization and kidney health. ec.bioscientifica.com

11. Monitoring plan (labs & ultrasound) – Purpose: catch complications early. Mechanism: periodic tests (phosphate, calcium, 1,25-OH₂D, urine calcium/creatinine) and renal imaging guide dose adjustments. PMC

12. Low-oxalate choices if stones are an issue – Purpose: reduce calcium oxalate stone formation. Mechanism: less oxalate in diet lowers urinary oxalate load and crystal formation with calcium. ScienceDirect

13. Maintain a healthy BMI – Purpose: decrease stone risk and joint stress. Mechanism: weight control improves urinary chemistry and reduces mechanical load on healing bones. ScienceDirect

14. Limit high-sugar sodas – Purpose: they may increase urinary calcium and stone risk. Mechanism: certain soft drinks alter urinary chemistry in ways that favor stones. ScienceDirect

15. Sunlight in moderation (for baseline vitamin D only) – Purpose: support normal 25-OH-D without overshooting active vitamin D. Mechanism: skin vitamin D becomes 25-OH-D; clinicians keep it normal while avoiding extra calcitriol. PMC

16. School and sports accommodations – Purpose: prevent injury during active rickets. Mechanism: adjust PE loads and allow hydration breaks to lower fracture and stone risk. ec.bioscientifica.com

17. Pain-coping skills & sleep hygiene – Purpose: manage chronic bone pain, improve quality of life. Mechanism: behavioral techniques reduce pain amplification and improve function. ec.bioscientifica.com

18. Family genetic counseling – Purpose: understand inheritance and testing of siblings. Mechanism: explains autosomal recessive risk and identifies heterozygous carriers who can have milder hypercalciuria. PMC

19. Sick-day hydration plan – Purpose: avoid dehydration-triggered stone events. Mechanism: replacing fluids during illness keeps urine dilute. ScienceDirect

20. Shared-care team (endocrine + nephrology + genetics + dietetics + physio) – Purpose: coordinate safe phosphate therapy and protect kidneys. Mechanism: team review ensures balance between bone healing and stone prevention. PMC+1

---

Drug treatments

Important: HHRH is not treated like XLH. In HHRH, clinicians usually give oral phosphate alone and avoid routine calcitriol, because calcitriol can worsen hypercalciuria and stones. Thiazide-type diuretics and potassium citrate may be added for kidney stone prevention if needed. Always dose and monitor with your specialist. PMC+1

1. Oral neutral phosphate salts (e.g., Phospha 250 Neutral) – Class: phosphate replacement. Dose/time: typically divided 3–5 times daily; the specific brand’s labeling guides tablet strength. Purpose & mechanism: directly restores blood phosphate so bones mineralize; lowers compensatory 1,25-OH₂D over time. Safety: GI upset possible; monitor calcium, phosphate, and kidneys. FDA materials describe composition/strengths. FDA Access Data

2. Potassium phosphates injection (hospital use) – Class: parenteral phosphate. Dose/time: IV infusion per labeling when oral/enteral replacement is not possible (e.g., severe symptomatic hypophosphatemia). Purpose & mechanism: rapidly corrects low phosphate. Safety: monitor electrolytes (phosphate, potassium, calcium, magnesium) and ECG during infusion. FDA Access Data+1

3. Hydrochlorothiazide – Class: thiazide diuretic. Typical dose/time: commonly 12.5–25 mg once daily (hypertension label); dosing for hypercalciuria is individualized. Purpose & mechanism: reduces urinary calcium; helps prevent stones from HHRH-related hypercalciuria. Key safety: can lower potassium and raise uric acid; monitor electrolytes. FDA Access Data

4. Chlorthalidone – Class: thiazide-like diuretic. Typical dose/time: 12.5–25 mg daily (per hypertension labels). Purpose/mechanism: long-acting option to reduce urinary calcium; chosen when hypercalciuria persists. Safety: watch for hypokalemia, volume depletion. FDA Access Data+1

5. Indapamide – Class: thiazide-like diuretic. Typical dose/time: 1.25–2.5 mg daily (label). Purpose/mechanism: alternative when HCTZ/chlorthalidone not tolerated. Safety: similar electrolyte risks; monitor. FDA Access Data+1

6. Amiloride – Class: potassium-sparing diuretic. Typical dose/time: 5–10 mg daily (label for hypertension/diuretic-induced hypokalemia). Purpose/mechanism: often combined with a thiazide to limit potassium loss and may modestly reduce urinary calcium. Safety: risk of hyperkalemia; avoid with kidney failure. FDA Access Data

7. Potassium citrate (Urocit-K) – Class: urinary alkalinizer/citrate. Typical dose/time: titrated to reach normal urinary citrate; label instructs pairing with low-salt diet and high fluids. Purpose/mechanism: citrate binds urinary calcium and inhibits calcium oxalate crystal growth, lowering stone risk in hypercalciuria. Safety: GI upset, hyperkalemia risk with certain drugs. FDA Access Data+1

8. Pain control (short-term acetaminophen under supervision) – Class: analgesic. Purpose/mechanism: symptom relief during active rickets while bone heals on phosphate therapy. Safety: follow package/clinician guidance for liver-safe dosing. (General standard; no FDA label citation needed beyond drug labeling norms.)

9. Avoid routine calcitriol (Rocaltrol) in HHRH – Why listed: many rickets types require calcitriol, but HHRH usually does not. Mechanism/purpose: in HHRH, endogenous 1,25-OH₂D is often already high; exogenous calcitriol would further raise urinary calcium. If ever used, it should be for specific indications under expert care with close urine calcium monitoring. Label note: calcitriol is FDA-approved vitamin D; this is a caution, not a recommendation. FDA Access Data+1

10. Citrate during thiazide therapy (adjunct) – Purpose/mechanism: when thiazides reduce urine calcium but citrate is still low, adding potassium citrate further reduces stone risk. Safety & dosing: per Urocit-K label; individualized targets. FDA Access Data

11. Electrolyte monitoring and repletion (e.g., potassium chloride as needed) – Purpose/mechanism: corrects thiazide-induced hypokalemia to maintain safety and treatment effectiveness. Label note: potassium chloride has detailed FDA labeling; clinicians dose to lab targets. FDA Access Data

12. Sodium restriction alongside thiazide – Purpose/mechanism: enhances anticalciuric effect of thiazides and reduces stone risk; implemented with or without Urocit-K per label guidance. FDA Access Data

13. Intravenous phosphate only when necessary – Purpose: rescue therapy for severe cases unable to take oral. Mechanism/safety: as above with potassium phosphates labeling. FDA Access Data

Additional prescription options are rarely required specifically for HHRH beyond the combinations above. Management focuses on oral phosphate, stone prevention (thiazide ± citrate, fluids, salt restriction), and careful monitoring; disease-specific biologics used for other rickets (e.g., burosumab for XLH) are not indicated in HHRH. NCBI

---

Dietary molecular supplements

These are adjuncts only. They do not replace medical phosphate or stone-prevention medicines. Always check interactions and labs with your clinician.

1. Citrate (as potassium citrate) – Function: raises urinary citrate, a natural stone inhibitor; may reduce calcium oxalate crystal formation. Mechanism: citrate binds calcium and alkalinizes urine. Dose: per Urocit-K label and clinic target. FDA Access Data

2. Magnesium (dietary / supplement, if low) – Function: low magnesium can worsen stone risk; normalizing helps. Mechanism: magnesium complexes with oxalate and reduces crystal formation. Dose: individualized by clinician. ScienceDirect

3. Adequate dietary calcium (avoid excess) – Function: supports bone; binds oxalate in gut. Mechanism: normal calcium intake reduces oxalate absorption. Dose: age-appropriate dietary targets. PMC

4. Phosphate-rich foods aligned with dosing plan – Function: complements divided phosphate therapy. Mechanism: small meal-time phosphate inputs support bone. ec.bioscientifica.com

5. Vitamin D (nutritional 25-OH-D only, if low) – Function: keep 25-OH-D in the normal range; avoid active vitamin D excess. Mechanism: supports general bone health without driving hypercalciuria. Dose: clinician-guided repletion to normal. PMC

6. Citrate-containing beverages (e.g., lemon water without sugar) – Function: modestly raises urinary citrate. Mechanism: alkali citrate intake can inhibit crystal growth. ScienceDirect

7. Low-oxalate choices when stones are calcium oxalate – Function: decreases urinary oxalate. Mechanism: less oxalate → fewer crystals with calcium. ScienceDirect

8. Adequate protein, not high-protein – Function: supports growth and repair. Mechanism: excessive animal protein can increase calciuria/acid load; balanced intake avoids that. ScienceDirect

9. Limit added sugars/sodas – Function: reduces stone risk and supports healthy weight. Mechanism: sugary sodas are associated with stone-promoting urine chemistry. ScienceDirect

10. Sodium reduction – Function: lowers urinary calcium. Mechanism: less sodium reabsorption trade-off reduces calciuria. FDA Access Data

---

Immunity booster / regenerative / stem cell drugs

There are no FDA-approved “immunity booster,” regenerative, or stem-cell drugs for HHRH. HHRH is a transporter defect of renal phosphate handling; management is replacement of phosphate and prevention of kidney complications. Using unproven “regenerative” or stem-cell products would be unsafe and is not recommended. FDA-approved phosphate products and thiazide/citrate labels above are the relevant drug sources. FDA Access Data+1

---

Surgeries

1. Orthopedic guided growth/osteotomy – Procedure to correct severe limb bowing or torsion if bracing and medical therapy are insufficient. Why: restores alignment for function and pain relief during/after bone healing. ec.bioscientifica.com

2. Ureteroscopy for obstructing stones – Endoscopic laser fragmentation and removal when a stone blocks urine flow. Why: relieves pain/obstruction from HHRH-related stones. ScienceDirect

3. Percutaneous nephrolithotomy – Keyhole removal of large kidney stones. Why: clears heavy stone burden (nephrocalcinosis with big stones). ScienceDirect

4. Shock-wave lithotripsy – External shock waves break stones into passable pieces. Why: treats selected stones depending on size and location. ScienceDirect

5. Corrective procedures for deformities affecting mobility – Tailored orthopedic operations if persistent deformities impair walking despite medical therapy. Why: improves quality of life. ec.bioscientifica.com

---

Preventions

• Take phosphate exactly as prescribed, in divided doses to keep blood phosphate steady and support bone. ec.bioscientifica.com

• Drink plenty of water every day to dilute urine and prevent stones. ScienceDirect

• Limit salt to reduce urinary calcium. FDA Access Data

• Do not take calcitriol unless your specialist prescribes it for a special reason, because it can worsen hypercalciuria in HHRH. PMC

• Follow a stone-smart diet (adequate calcium, lower oxalate, minimal sugary soda). ScienceDirect

• Keep 25-OH-vitamin D in the normal range (not high). PMC

• Use thiazide ± potassium citrate if your doctor recommends them for persistent hypercalciuria. FDA Access Data+1

• Attend regular lab and ultrasound checks to adjust doses early. PMC

• Protect bones with safe activity and physiotherapy during healing. ec.bioscientifica.com

• Plan for illness/heat with extra fluids to avoid concentrated urine. ScienceDirect

---

When to see a doctor

• New or worsening bone pain, bowing, limping, or fractures → clinic/ED review. PMC

• Kidney stone symptoms (severe flank pain, blood in urine, fever, vomiting, trouble passing urine) → urgent care/ER. ScienceDirect

• Signs of electrolyte problems on thiazides (muscle cramps, weakness, light-headedness) → prompt labs. FDA Access Data

• If pregnant or planning pregnancy → preconception counseling for genetic risk and medication review. PMC

• Any time doses change (phosphate, thiazide, citrate) → monitoring plan update. PMC

---

What to eat & what to avoid

• Eat: normal-calcium foods (milk/yogurt in usual amounts), legumes/lean meats for protein, fruits/vegetables (many provide potassium/citrate), whole grains, and plenty of water across the day. ScienceDirect

• Avoid/limit: very salty foods (chips, processed meats), sugary sodas/colas, excessive animal protein, large single boluses of calcium or vitamin D supplements without medical advice, and dehydration (especially in heat/exercise). ScienceDirect

---

FAQs

1) How is HHRH different from the common X-linked rickets (XLH)?
HHRH has hypercalciuria and typically high 1,25-OH₂D with low/normal FGF23; XLH has low 1,25-OH₂D with high FGF23 and usually normal urine calcium. NCBI

2) What gene is involved?
Most HHRH is due to SLC34A3 (NaPi-IIc) variants. PubMed

3) Is calcitriol helpful?
Usually no—it can worsen hypercalciuria in HHRH; treatment usually focuses on oral phosphate. PMC

4) Why do kidney stones happen?
Extra active vitamin D increases gut calcium absorption → more urinary calcium → stones/nephrocalcinosis. PMC

5) Do carriers have symptoms?
Some heterozygous carriers may have milder biochemical changes resembling idiopathic hypercalciuria. PMC

6) What tests confirm the diagnosis?
Low serum phosphate, high urinary phosphate wasting (low TmP/GFR), high 1,25-OH₂D, hypercalciuria, and SLC34A3 sequencing. PMC

7) How is phosphate taken?
Divided oral doses 3–5 times daily; dose is individualized and adjusted to labs and growth. ec.bioscientifica.com

8) Can thiazide pills help?
Yes—when hypercalciuria persists, thiazides (e.g., hydrochlorothiazide or chlorthalidone) reduce urinary calcium. FDA Access Data+1

9) Why add potassium citrate?
It raises urinary citrate, which binds calcium and slows crystal formation—a standard stone-prevention tool. FDA Access Data

10) Are there FDA-approved regenerative or stem-cell drugs for HHRH?
No; management relies on phosphate replacement and stone prevention, not regenerative drugs. FDA Access Data

11) Will my child’s bones get better?
With early diagnosis, correct phosphate therapy, and stone prevention, bones usually mineralize and pain/function improve. Monitoring continues through growth. PMC

12) Can HHRH be missed if vitamin D is low?
Yes—vitamin D deficiency can mask the typical pattern; once corrected, the characteristic labs (including hypercalciuria) re-appear. Kidney International+1

13) Do I need genetic counseling?
Helpful for family planning and sibling testing in this autosomal recessive condition. PMC

14) What imaging is needed?
Renal ultrasound for stones/nephrocalcinosis and X-rays for rickets/osteomalacia. ScienceDirect

15) Are XLH medicines (like burosumab) used here?
No—those target FGF23 excess (not the problem in HHRH). NCBI

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 07, 2025.